Literature DB >> 12595539

JAK2/STAT3, not ERK1/2, mediates interleukin-6-induced activation of inducible nitric-oxide synthase and decrease in contractility of adult ventricular myocytes.

XinWen Yu1, Richard H Kennedy, Shi J Liu.   

Abstract

Interleukin (IL)-6 decreases cardiac contractility via a nitric oxide (NO)-dependent pathway. However, mechanisms underlying IL-6-induced NO production remain unclear. JAK2/STAT3 and ERK1/2 are two well known signaling pathways activated by IL-6 in non-cardiac cells. However, these IL-6-activated pathways have not been identified in adult cardiac myocytes. In this study, we identified activation of these two pathways during IL-6 stimulation and examined their roles in IL-6-induced NO production and decrease in contractility of adult ventricular myocytes. IL-6 increased phosphorylation of STAT3 (at Tyr(705)) and ERK1/2 (at Tyr(204)) within 5 min that peaked at 15-30 min and returned to basal levels at 2 h. Phosphorylation of STAT3 was blocked by genistein, a protein tyrosine kinase inhibitor, and AG490, a JAK2 inhibitor, but not PD98059, an ERK1/2 kinase inhibitor. The phosphorylation of ERK1/2 was blocked by PD98059 and genistein but not AG490. Furthermore, IL-6 enhanced de novo synthesis of iNOS protein, increased NO production, and decreased cardiac contractility after 2 h of incubation. These effects were blocked by genistein and AG490 but not PD98059. We conclude that IL-6 activated independently the JAK2/STAT3 and ERK1/2 pathways, but only JAK2/STAT3 signaling mediated the NO-associated decrease in contractility.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12595539     DOI: 10.1074/jbc.M212321200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  51 in total

1.  A role of PPAR-gamma in androstenediol-mediated salutary effects on cardiac function following trauma-hemorrhage.

Authors:  Tomoharu Shimizu; László Szalay; Ya-Ching Hsieh; Takao Suzuki; Mashkoor A Choudhry; Kirby I Bland; Irshad H Chaudry
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

Review 2.  Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure.

Authors:  Toshinori Aoyagi; Takashi Matsui
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

3.  IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis.

Authors:  Adam I Kaplin; Deepa M Deshpande; Erick Scott; Chitra Krishnan; Jessica S Carmen; Irina Shats; Tara Martinez; Jennifer Drummond; Sonny Dike; Mikhail Pletnikov; Sanjay C Keswani; Timothy H Moran; Carlos A Pardo; Peter A Calabresi; Douglas A Kerr
Journal:  J Clin Invest       Date:  2005-09-22       Impact factor: 14.808

4.  Inducible nitric oxide synthase is a major intermediate in signaling pathways for the survival of plasma cells.

Authors:  Ankur S Saini; Gautam N Shenoy; Satyajit Rath; Vineeta Bal; Anna George
Journal:  Nat Immunol       Date:  2014-01-19       Impact factor: 25.606

5.  Skeletal muscle function during the progression of cancer cachexia in the male ApcMin/+ mouse.

Authors:  Brandon N VanderVeen; Justin P Hardee; Dennis K Fix; James A Carson
Journal:  J Appl Physiol (1985)       Date:  2017-11-09

Review 6.  Reappraising the role of inflammation in heart failure.

Authors:  Luigi Adamo; Cibele Rocha-Resende; Sumanth D Prabhu; Douglas L Mann
Journal:  Nat Rev Cardiol       Date:  2020-01-22       Impact factor: 32.419

7.  Inhibition of sarcoplasmic reticular function by chronic interleukin-6 exposure via iNOS in adult ventricular myocytes.

Authors:  Xin-Wen Yu; Qian Chen; Richard H Kennedy; Shi J Liu
Journal:  J Physiol       Date:  2005-04-21       Impact factor: 5.182

8.  Targeting myeloid-derived suppressor cells using a novel adenosine monophosphate-activated protein kinase (AMPK) activator.

Authors:  Prashant Trikha; Robert L Plews; Andrew Stiff; Shalini Gautam; Vincent Hsu; David Abood; Robert Wesolowski; Ian Landi; Xiaokui Mo; John Phay; Ching-Shih Chen; John Byrd; Michael Caligiuri; Susheela Tridandapani; William Carson
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

Review 9.  The varying faces of IL-6: From cardiac protection to cardiac failure.

Authors:  Jillian A Fontes; Noel R Rose; Daniela Čiháková
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

10.  Reversible cardiomyopathy associated with Multicentric Castleman disease: successful treatment with tocilizumab, an anti-interleukin 6 receptor antibody.

Authors:  Junya Kanda; Hiroshi Kawabata; Yuhei Yamaji; Tatsuo Ichinohe; Takayuki Ishikawa; Toshihiro Tamura; Yutaka Furukawa; Takeshi Kimura; Toru Kita; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2007-04       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.